Free Trial

Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis

+0.10 (+0.26%)
(As of 06/18/2024 ET)
Today's Range
50-Day Range
52-Week Range
3,214 shs
Average Volume
11,137 shs
Market Capitalization
$1.16 billion
P/E Ratio
Dividend Yield
Price Target

Calliditas Therapeutics AB (publ) MarketRank™ Stock Analysis

Analyst Rating
2.00 Rating Score
10.4% Downside
$35.00 Price Target
Short Interest
0.03% of Shares Sold Short
Dividend Strength
News Sentiment
0.97mentions of Calliditas Therapeutics AB (publ) in the last 14 days
Based on 6 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.86) to $3.64 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.10 out of 5 stars

Medical Sector

755th out of 913 stocks

Pharmaceutical Preparations Industry

354th out of 430 stocks

CALT stock logo

About Calliditas Therapeutics AB (publ) Stock (NASDAQ:CALT)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

CALT Stock Price History

CALT Stock News Headlines

Calliditas provides setanaxib patent update
Musk’s new company could top a trillion?
The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.
Musk’s new company could top a trillion?
The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.
Calliditas Q1 report, January - March 2024
Calliditas Q1 report, January - March 2024
See More Headlines
Receive CALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$113.78 million
Book Value
$1.06 per share


Free Float
Market Cap
$1.16 billion

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Ms. Renee Aguiar-Lucander (Age 62)
    Chief Executive Officer
    Comp: $11.72M
  • Mr. Fredrik Johansson (Age 47)
    Chief Financial Officer
  • Lars Stubberud (Age 60)
    Head of Technical Operations
  • Ms. Asa Hillsten (Age 49)
    Head of IR & Sustainability
  • Mr. Brian Gorman (Age 48)
    Group General Counsel
  • Ms. Sandra Frithiof (Age 49)
    Head of Human Resources
  • Ms. Ann-Kristin Myde BSc (Age 69)
    Head of Clinical Development & VP of Project Management
  • Dr. Richard S. Philipson M.D. (Age 60)
    Chief Medical Officer
  • Ms. Teona Johnson
    Head of US Marketing
  • Mr. David Ferraro
    Head of US Sales

CALT Stock Analysis - Frequently Asked Questions

Should I buy or sell Calliditas Therapeutics AB (publ) stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calliditas Therapeutics AB (publ) in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CALT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CALT, but not buy additional shares or sell existing shares.
View CALT analyst ratings
or view top-rated stocks.

What is Calliditas Therapeutics AB (publ)'s stock price target for 2024?

6 Wall Street research analysts have issued twelve-month price targets for Calliditas Therapeutics AB (publ)'s stock. Their CALT share price targets range from $18.00 to $40.00. On average, they expect the company's stock price to reach $35.00 in the next year. This suggests that the stock has a possible downside of 10.4%.
View analysts price targets for CALT
or view top-rated stocks among Wall Street analysts.

How have CALT shares performed in 2024?

Calliditas Therapeutics AB (publ)'s stock was trading at $25.74 at the beginning of 2024. Since then, CALT stock has increased by 51.7% and is now trading at $39.05.
View the best growth stocks for 2024 here

Are investors shorting Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 8,200 shares, a decrease of 16.3% from the May 15th total of 9,800 shares. Based on an average daily volume of 12,200 shares, the days-to-cover ratio is presently 0.7 days.
View Calliditas Therapeutics AB (publ)'s Short Interest

When is Calliditas Therapeutics AB (publ)'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 15th 2024.
View our CALT earnings forecast

How were Calliditas Therapeutics AB (publ)'s earnings last quarter?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) announced its earnings results on Thursday, May, 23rd. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.74. The business had revenue of $28.43 million for the quarter, compared to analyst estimates of $35.78 million. Calliditas Therapeutics AB (publ) had a negative trailing twelve-month return on equity of 160.87% and a negative net margin of 40.19%.

What other stocks do shareholders of Calliditas Therapeutics AB (publ) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calliditas Therapeutics AB (publ) investors own include Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CTI BioPharma (CTIC), DRDGOLD (DRD), Forte Biosciences (FBRX).

When did Calliditas Therapeutics AB (publ) IPO?

Calliditas Therapeutics AB (publ) (CALT) raised $179 million in an initial public offering on Friday, June 5th 2020. The company issued 9,200,000 shares at $19.50 per share. Citigroup, Jefferies and Stifel acted as the underwriters for the IPO and Carnegie was co-manager.

Who are Calliditas Therapeutics AB (publ)'s major shareholders?

Calliditas Therapeutics AB (publ)'s stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Calliditas Therapeutics AB (publ)?

Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CALT) was last updated on 6/18/2024 by Staff

From Our Partners